How should biomarkers for safety be identified and selected?

被引：0
|
作者：
Wärngärd, L [1 ]
机构：
[1] VINNOVA, Dept Biotechnol, SE-10158 Stockholm, Sweden
来源：
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2004年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [41] Biomarkers of kidney transplant rejection identified
    Hill, Rosanna
    BIOANALYSIS, 2013, 5 (16) : 1947 - 1947
  • [42] Predictive biomarkers identified for renal denervation
    Nature Reviews Nephrology, 2014, 10 (4) : 182 - 182
  • [43] How Should Patients With Progressive Pulmonary Fibrosis Be Identified? Consensus Findings From a Modified Delphi Study
    Wells, A. U.
    Walsh, S. L. F.
    Adegunsoye, A.
    Cottin, V.
    Danoff, S.
    Devaraj, A.
    Flaherty, K. R.
    George, P. M.
    Johannson, K. A.
    Kolb, M.
    Kondoh, Y.
    Nicholson, A. G.
    Tomassetti, S.
    Volkmann, E. R.
    Brown, K. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [44] NUTRITION - HOW IT IS AND HOW IT SHOULD BE
    SCHLIERF, G
    FETTE SEIFEN ANSTRICHMITTEL, 1982, 84 (08): : 326 - 326
  • [45] MAINTENANCE - NOT HOW IT IS - BUT HOW IT SHOULD BE
    JENNINGS, H
    AMERICAN DAIRY REVIEW, 1971, 33 (05): : 53 - &
  • [46] How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?
    Pawel Rajwa
    Jamil Syed
    Michael S. Leapman
    Abdominal Radiology, 2020, 45 : 4031 - 4039
  • [47] How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?
    Rajwa, Pawel
    Syed, Jamil
    Leapman, Michael S.
    ABDOMINAL RADIOLOGY, 2020, 45 (12) : 4031 - 4039
  • [48] How should biometrics be used and how should it absolutely not be used?
    Pfitzmann, Andreas
    Informatik-Spektrum, 2006, 29 (05) : 353 - 356
  • [49] The cost of safety - Part 1 of 2 - What is the true cost of mill workplace safety and how should it be determined?
    Little, John E.
    PULP & PAPER-CANADA, 2007, 108 (02) : 54 - 54
  • [50] Conflicts of Interest in Medicines Safety and Regulation How Much Conflict and How Much Interest Should We Allow?
    Edwards, I. Ralph
    DRUG SAFETY, 2011, 34 (08) : 617 - 621
12345